Latest contributions
What does ORBITA CTO tell us about CTO PCI?
20 May 2026 – From EuroPCR 2026
Chronic total occlusions (CTOs) remain a key area of uncertainty in interventional cardiology, particularly regarding symptom improvement after PCI.
In this EuroPCR 2026 interview, John Davies and Sarosh Khan discuss the ORBITA CTO trial and its implications for clinical practice.
As the first double-blind, placebo-controlled randomised trial in...
A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina - ORBITA-CTO trial
03 Apr 2026
Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...
Author
Author
Author
New data on TAVI
16 May 2024 – From EuroPCR 2024
This session presents the latest research and data on transcatheter aortic valve implantation (TAVI). It covers a range of topics, including long-term results of TAVI versus surgical aortic valve replacement in low-risk severe aortic stenosis, real-world experience with novel transcatheter heart valve devices, outcomes in patients...
